drugset / Trial / NCT01248130

Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders

NCT01248130

Phase 2 Terminated 7 enrolled Massachusetts General Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary aim of this study is to examine the efficacy and tolerability of short-term omega-3 fatty acids monotherapy in youth with Autism Spectrum Disorders (ASD). The investigators hypothesize that Omega-3 fatty acids will be efficacious in improving the core and associated features of ASD in youth, and that Omega-3 fatty acids monotherapy will be safe and well tolerated by youth with ASD. The secondary aim of this study is to examine the neuropsychological effect of Omega-3 fatty acids monotherapy in youth with ASD. The investigators hypothesize that omega-3 fatty acids will be efficacious in improving cognitive functions in youth with ASD.

Timeline

Start
2009-11
Primary completion
2013-04
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lovaza Other / unclassified 1500 mg